NanoLogix Company Updates

2016

  • Jan 11, 2016:
    NanoLogix Announces Publication of a Study in Journal of Microbiology and Experimentation

    HUBBARD, OH--(Marketwired - Jan 5, 2016) - NanoLogix, Inc. ( OTC PINK : NNLX ), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce publication in the Journal of Microbiology and Experimentation of a peer-reviewed study demonstrating dramatically extended shelf life and high-temperature durability of filled petri plates packed in NanoLogix-manufactured gas-charged FlatPacks. The study was performed by one of the world's largest and most prestigious Biomedical Research Centers.
    more>>>

2015

  • Dec 21, 2015:
    NanoLogix Announces Diagnostic Customization for Major Medical Device Company

    NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
    more>>>
  • Oct 26, 2015:
    NanoLogix BioTechnology announces:


    1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least. The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.

    2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products

    3) NanoLogix has reached an agreement with a multi-billion dollar medical technology company to customize the N-Assay diagnostic technology for their requirements. The work is being financed by the client and upon successful completion is projected to result in sales of multiple thousands of N-Assay kits.

    4) The largest single-customer, single-day sale in the history of the company has just occurred , for an amount in excess of $30,000.00 The order was for agar-filled petri plates.


    Note: The company and its management have received numerous communications from shareholders concerned with the perceived delay in results of the N-Assay study and how the N-Assay fits with the BNF technology. The answer to these queries is this: Researchers were furnished batches of antibodies from the premier antibody suppliers in the United States. When those antibodies are not of the quality previously received from the suppliers, then other premier suppliers are sourced. This is not an instant process. Under personnel and financial resource constraints previously addressed, what NanoLogix BioTechnolgy does should not be viewed as one would view what major biotech accomplish for timelines. The N-Assay is a non-subjective, computer-readable ELISA diagnostic. The BNF is not, period. We will focus upon what is the best technology, which is the N-Assay.

    All of this information, and more, will soon be released in a public press release for the use of the media.
  • July 1, 2015:
    BNF Patent Granted - US Patent #9,068,216

    The Company is pleased to announce the United States Patent and Trademark Office has granted U.S. Patent 9,068,216 on 30 June 2015 for:
    Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes
    Abstract
    The invention provides methods, devices and kits for rapid detection and identification of one or more live target microorganisms in a liquid sample or grown on plates containing nutrient media. The invention includes mixing one or more target microorganisms with one or more aptamers and/or one or more antibodies, each conjugated to a reporter compound and specific for a first site on or more target microorganisms to form a mixture. The mixture is placed on a permeable membrane having immobilized thereon one or more aptamers linked to an amine compound, and/or one or more antibodies, each specific for a second site on one or more target microorganisms or a site on the aptamer conjugate and/or antibody conjugate. A detection solution is added to the membrane and detection and identification of one or more target microorganisms is achieved in about one hour or less. In other news, NanoLogix also takes this opportunity to thank Professor Daniel Barnhizer for over six years of service on the Board of Directors. In light of current health issues and obligations at his law school regarding work for outside firms, Professor Barnhizer has resigned from the Board of Directors effective 1 July 2015. Professor Barnhizer will continue to assist the company on an as-needed basis.
  • June 17, 2015:
    Notification received from Peoples Republic of China for grant of FlatPack packaging patent

    In early June, notification of "Grant Patent Right for Invention" was received from the China Patent intellectual Property Office in Beijing, People's Republic of China (PRC) for the FlatPack petri plate packaging invention. The Patent provides intellectual property protection in the PRC, a country with nearly 19% of the world's population. The Company expects the patent to provide assistance in marketing for our Singaporean representatives and anticipates sub-licensing rights for use and manufacture to a group or groups in the region. The multiple claims of the patent allowed in the USPTO Patent Grant 8,413,800 were accepted as presented:

    1. A flat package containing a plurality of petri dishes for prolonged shelf life and preservation thereof, comprising: an optically clear, high-barrier, moisture-, gas- and microbial-resistant pouch containing a plurality of sterile petri dishes therein, said pouch having an interior cavity, each of said plurality of petri dishes located adjacent one another within the interior cavity of the pouch, wherein the clarity of the pouch and the placement of the petri dishes therein allow for prolonged shelf life and preservation of sterility of the petri dishes, reduced mobility of the petri dishes, and enhanced visibility of each of the petri dishes by a user.
    2. The flat package according to claim 1, wherein the plurality of petri dishes are aligned in one plane of the pouch.
    3. The flat package according to claim 1, wherein the pouch is comprised of a visibly clear plastic material selected from the group consisting of polypropylene, oriented polypropylene (OPP), polyethylene terephthalate (PET) and combinations thereof.
    4. The flat package according to claim 1, wherein a vacuum is applied to the interior cavity of the pouch to evacuate atmospheric air therefrom.
    5. The flat package according to claim 1, wherein the interior cavity of the pouch optionally is flushed with an inert gas after application of the vacuum.
    6. The flat package according to claim 1, wherein the inert gas is nitrogen gas.
    7. The flat package according to claim 1, wherein the pouch is heat sealed after application of the vacuum and, optionally, being flushed with the inert gas.
    8. The flat package according to claim 1, wherein the pouch has an easy open means such as a zip-lock.
    9. The flat package according to claim 1, wherein the pouch and the plurality of petri dishes are handled aseptically in an aseptic environment.
    10. The flat package according to claim 1, wherein the plurality of petri dishes consists of about ten to about twenty petri dishes.
    11. The flat package according to claim 1, wherein the shape of the pouch is selected from the group consisting of circular, rectangular, elliptical and square.
    12. The flat package according to claim 1, wherein the plurality of petri dishes has a shelf life and remains sterile for at least twelve months.
    13. A method of producing a flat package containing a plurality of petri dishes for prolonged shelf life and preservation thereof, comprising: obtaining an optically clear, high-barrier, moisture-, gas- and microbial-resistant pouch, said pouch having an interior cavity; inserting a plurality of petri dishes within the interior cavity of the pouch, each of said plurality of petri dishes located adjacent to another petri dish; applying a vacuum to the pouch to evacuate atmospheric air from the pouch and the plurality of petri dishes; optionally flushing the pouch with an inert gas; and heat sealing the pouch, wherein the clarity of the pouch and the placement of the petri dishes therein allow for prolonged shelf life and preservation of sterility of the petri dishes, reduced mobility of the petri dishes in the pouch, and enhanced visibility of each of the petri dishes by a user.
    14. The method according to claim 13, wherein the plurality of petri dishes are aligned in one plane of the pouch.
    15. The method according to claim 13, wherein the pouch is comprised of a visibly clear plastic material selected from the group consisting of polypropylene, oriented polypropylene (OPP), polyethylene terephthalate (PET) and combinations thereof.
    16. The method according to claim 13, wherein the inert gas is nitrogen gas.
    17. The method according to claim 13, wherein the sealed pouch has an easy open means such as a zip-lock.
    18. The method according to claim 13, wherein the pouch and the plurality of petri dishes are handled aseptically in an aseptic environment.
    19. The method according to claim 13, wherein the plurality of petri dishes consists of about ten to about twenty petri dishes.
    20. The method according to claim 13, wherein the plurality of petri dishes has a shelf life and remains sterile for at least twelve months.
  • June 16, 2015:
    NanoLogix expands choices for order configuration

    In order to better satisfy customer needs, effective July 1, 2015, NanoLogix will offer Flatpack petri plate configurations in Flatpacks of 20, 30, 40 and 50 plates in addition to the standard 10 and 25 plates currently supplied. This move is done to assist high-use current and potential customers in reducing both their labor for handling in the laboratory and overall packaging waste disposal costs. The company anticipates this move will further increase the attractiveness of NanoLogix petri plates to present and potential customers.
  • May 04, 2015:
    Rapid Tests for Fungal Infections
    The industry demands diagnostic tests that are fast, sensitive and easy to use more>>>
  • Feb, 2015 NanoLogix is pleased to announce receipt of notification of allowance and/or granting of patents in the US and internationally for:
    USA: BNF for use with Antibodies and Aptamers USA: N-Assay Rapid Detection Technology China: FlatPack Packaging New Zealand: FlatPack Packaging The allowance and upcoming grants of patents significantly strengthen the position of the Company's intellectual property both domestically and internationally.
  • Jan, 2015 NanoLogix is pleased to share the following information:
    In recent and ongoing work, researchers in the United States have confirmed the potential efficacy of NanoLogix's N-Assay as a rapid indicator for the presence of the current-threat strain of the Ebola virus, EBOV. The research demonstrates a sub-three hour result at present. Researchers are working to refine the test and reduce time-to-detection to facilitate the N-Assay's use as a Point of Care (POC) diagnostic for hemorrhagic and other viruses.

2014

  • June 4, 2014 Nanologix® YSU business students learn by doing NanoLogix is pleased to have been mentioned in a news update from Youngstown State University's Williamson College of Business Administration. The update focused upon the participation of seven area companies that worked with students on their Exporting Course projects for assessing international marketing potential. The assessments were performed utilizing a powerful marketing resource database available through the University and the State of Ohio. The management and staff of NanoLogix, as a member of the local business community and as a current exporter to a number of countries, view participation in educational projects such as this as part of their duty to that community. We are pleased to have been able to contribute to the education of students about to enter their business careers. Read more>>>
  • May 20, 2014 Nanologix® NewsWire: Nanologix Exhibits at ASM Annual Meeting in Boston and welcomes VP for Sales and Marketing Read more>>>
  • May 16, 2014:
    Nanologix: William Hank Lewis Takes Role as VP of Sales and Marketing
    I am extremely excited to be part of Nanologix and work with the team to take our sales to the next level,” said Lewis. “I plan to hit the ground running to assess our customer base, drive reorders and customer retention, develop new customer bases and expand our footprint in the multiple segments that can benefit from our pioneering technology.” Hank brings three decades of experience in selling, marketing and management experience in the pharmaceutical, genetics, genomics, and complex molecular laboratory sector. His career has included management positions at Knoll Pharmaceuticals, Novartis, and Myriad Genetics. Most recently, Hank was a Sales Manager with CardioDx, a cardiovascular molecular diagnostic CLIA laboratory, where he was responsible for managing a team of field sales representatives in seven states. Hank not only has the reputation for building high performing teams, but for being creative when it comes to sales and marketing, and for fostering cross-functional teamwork with internal departments to achieve common goals and drive operational excellence. After graduating from Berea College in Kentucky, with a BS degree in Business Management, Hank began his career in retail, moving to Columbus Ohio, where he became Assistant VP of Store Operations for the Kobacker Company. He then transitioned into the medical/diagnostic life science business sector, where, through his leadership, his teams earned regional and national awards for their sales successes. Hank has extensive experience in budget management, long term planning, and pragmatic goal-oriented selling.
  • April 14, 2014:
    News: Article NanoLogix's new N-Assay rapid test discussed in article by Dr. Jonathan Faro in latest issue of Med Lab Observer. more>>>
  • April 11, 2014:
    Saudi Arabia FDA listing NanoLogix was informed today that Nasaem AlJazira has received notification their application for Saudi Arabian MDNR (Medical Device National Registration) listing for NanoLogix products has been approved. Saudi Arabia FDA approval is pending.
  • April 11, 2014:
    NanoLogix personnel staffed booth 625 at the Food Safety Summit in the Baltimore Convention Center April 9-10. Interest in NanoLogix products and technology was very strong, with food producers, food testing facilities, general laboratories, Federal government agencies, venture capital and investment groups discussing topics from use of NanoLogix products through partnerships and more.
  • March 23, 2014:
    Hubbard firm sets new standards in detecting deadly diseases, Research going on quietly inside a nondescript Hubbard building is setting a new worldwide standard for the speed in which infectious disease can be diagnosed or dangerous microorganisms like tuberculosis, anthrax or group B streptococcus can be detected. more>>>
  • Feb 25, 2014:
    NanoLogix Signs Asia Distribution Agreement with IVD Tech of Singapore, NanoLogix Inc. (OTCBB:NNLX) NanoLogix, an innovator in the rapid detection, identification and determination of antibiotic resistance and sensitivity of live bacteria, announces that they have signed a distribution agreement with IVD Tech Private Ltd of Singapore. This distribution agreement provides IVD Tech with exclusive distribution rights for sales of NanoLogix products in a number of Asian countries. The agreement was finalized and signed in Hubbard Ohio with the help of Mousa Kassis, representative of the Ohio International Trade Assistance Center (ITAC) housed at Youngstown State University. more >>>
  • Feb 24, 2014:
    NanoLogix Petri technology sets new record for shelf life, NanoLogix has been informed by an independent third-party* testing facility that the ongoing room temperature shelf life test results from 7 Feb 2014 have successfully reached the 19-month point with NanoLogix Tryptic Soy Agar (TSA) plates packed in FlatPacks in July 2012 performing as well as one-week old competitor's plates. In this ongoing study, NanoLogix TSA petri plate shelf life has reached nearly 10 times the competition's room temperature shelf life of slightly over 2 months. Prior to this study, the standard for storage of TSA petri plates was for cold storage only, for a period of 3-1/2 months. In internal company cold storage tests, NanoLogix plates are approaching the three-year point with no loss of viability. The importance of these results cannot be overstated --- growth media and petri plates have historically been mixed and filled (or poured) in locations that are limited to the states, regions, or countries in which the users are located due to the perishable nature of the products. The long shelf life of our products, and resistance to breakage in shipment of NanoLogix products are producing a paradigm shift on the part of those who are the product end users to one where they can now take delivery of our products thousands of miles distant from the production location and be assured that they have a product that significantly outlasts others made onsite or locally. A number of our petri-based products can be stored at room temperature for months or more, a feature that is unique to NanoLogix products and one that reduces energy requirements significantly on projects both large and small, with no need for cold storage equipment for our TSA (19+ months), Nematode Growth Media (12+ months), Chocolate Agar (10+ months) petri plates.

    *NanoLogix is prohibited by contract from revealing the identity of the main third-party entity with which they work. more >>>
  • Jan 29, 2014:
    Fetured in Business Journal Daily News, BioTechnology Drives Market for NanoLogix more >>>
  • Jan 17, 2014:
    The International Trade Assistance Center (ITAC) located in the Williamson College of Business Administration at Youngstown State University (YSU) continues to support growth with international trade by extending support and facilitating the international distribution of products between NanoLogix, Inc. and Nasaem Al-Jazira, Inc. more >>>

2013

    April 30, 2013

    Company Update

    The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

    New Technologies

    The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.

    In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

    Scholarship and Research on NanoLogix Technologies

    In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. http://www.hindawi.com/journals/idog/2013/367935/

    New License and Patents

    The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack® packaging technology, to which NanoLogix has an exclusive license. The FlatPack® technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack® Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco

    Marketing

    In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

    Financial Matters

    As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000.  That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

    In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

  • Dec 24, 2013:

    NanoLogix is pleased to announce the addition of new member to the Science Advisory Board:

    Dr. Sebastian Faro rejoins the SAB after an absence of over a year when he resigned due to a policy change at UTHSC-Houston that required all personnel affiliated with UTHSC to shed any corporate associations. Dr. Faro is now affiliated with The Woman's Hospital of Houston, which does not restrict physicians. associations. The company welcomes Dr. Faro back to the Science Advisory Board.

  • Dec 15, 2013:
    NanoLogix Inc. Russia has granted and issued a patent to NanoLogix for its BNP detection technology. This is the second international patent granted for BNP in 2013, with grant and issuance by Japan earlier this year.
  • Dec 15, 2013:
    NanoLogix Inc. In the World Health Organization's Global Tuberculosis Report 2013 on page 87, NanoLogix' BNP Middlebrook test has been mentioned as a "culture based technology in early development". The BNP Middlebrook provided evidence of live TB growth in 5 days in tests by the world's largest private Research and Development corporation. Tests for screening for TB in blood at the same facility using NanoLogix BNF technology provided positive results in roughly 1-1/2 hours. Both test results are important in the battle against TB, with standard sputum culture results taking roughly three weeks and rapid blood screening tests, critical in the diagnosis of pediatric TB, as children do not produce sputum, taking many hours.
    In the World Health Organization's Global Tuberculosis Report 2013 on page 87, NanoLogix' BNP Middlebrook test has been mentioned as a "culture based technology in early development"
  • Dec 4, 2013:
    NanoLogix Inc. Announces additional product offerings with E-Beam sterilization process
    NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region
  • August 18, 2013:
    Dr Jonathan Faro of the UTHSC at Houston presented two posters at the IDSOG meeting in Albuquerque showing the results of tests with NanoLogix BNF and new Multiwell N-Assay diagnostics. The N-Assay delivered 30 minute results for detection and identification of Group B Streptococcus (GBS) while the BNF provided detection, identification, and determination of sensitivity to clindamycin antibiotic in 6 - 6.5 hours. Both tests are significantly faster than the standard tests in use, which take 48-72 hours for the same results. The significance of the results and impact upon screening for GBS in pregnancies, and potentially in the elderly and immuno-compromised patients of all ages, is tremendous.
    1. FC-Fragment.pdf
    2. Clinda.pdf
  • August 06, 2013:
    NanoLogix Inc. Report on technologies
    To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and..
  • June 21, 2013:
    NanoLogix Inc. Report on technologies
    June 21, 2013 Video instructional update for use of BNP kits
  • Jun 11, 2013: Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>

  • April 30, 2013:
    NanoLogix Inc. Report on technologies

    The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

    New Technologies

    The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.

    In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

    Scholarship and Research on NanoLogix Technologies

    In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. http://www.hindawi.com/journals/idog/2013/367935/

    New License and Patents

    The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack® packaging technology, to which NanoLogix has an exclusive license. The FlatPack® technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack® Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco

    Marketing

    In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

    Financial Matters

    As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000.  That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors *** the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

    In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

  • April 05, 2013:
    NanoLogix plans to begin marketing this summer of their new N-Assay Multiwell Diagnostic test. The N-Assay is a machine-readable test that will be available in an assortment of size configurations for detection and identification of a variety of bacteria. Tests to date have provided consistent results in as little as 30 minutes with both high sensitivity and specificity.
  • April 02, 2013:
    NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.
  • Jan 22, 2013: NanoLogix Inc is pleased to announce that the results of the University of Texas Health Science Center - Houston (UTHSC - Houston) Clinical Study utilizing NanoLogix's BNF technology to detect and identify Group B Streptococcus in pregnant patients have been accepted for publication in a noted peer-reviewed journal. The 352-patient Clinical Study was performed from March 2011 through May 2012 at Memorial Hermann Hospital in Houston. In the study, times for detection and identification of GBS were reduced from 48-72 hours to 4-6 hours. In accordance with journal protocols and preservation of pre-release confidentiality, further details will be released upon publication.

2012

  • Nov 9, 2012: NanoLogix Subject of EPA Featured News article, NanoLogix's Cooperative Research and Development Agreement (CRADA) with the US Environmental Protection Agency is covered in an article posted this week on the EPA's internal news site: The article covers current and projected aspects of the CRADA. Focus is on the ongoing joint development efforts of the EPA and NanoLogix related to creation of a comprehensive water quality test kit for use in all ten EPA regions. The current scope of the effort is focused on testing of drinking and source water. Read more
  • Aug 21, 2012: Hubbard, OH, August 21, 2012 . NanoLogix (OTC Markets: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria and microorganisms, announces it will begin commercialization of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first product to be marketed will be the Petri-based BNP detection kit utilizing TSA media. Other nutrient media will be available by special order. Recently completed independent third-party research has demonstrated BNP diagnostic kits to be two to ten times faster at live bacteria detection than traditional methods. Following the BNP rollout, NanoLogix plans to commercialize its BNF technology, which third-party research documents as 18 to 72 times faster than conventional detection and identification methods. The company also plans to develop customized test kits for particular applications and client partners.
    Peer-Reviewed Research Pending Publication The results of two independent third-party research studies using NanoLogix technology have been submitted by their respective organizations to major peer-reviewed medical technology journals for publication. The first submission details the use of NanoLogix BNF test kits and final results of a 356 pregnant-patient Group B Streptococcus (GBS) clinical study at the University of Texas Health Science Center - Houston. This study attained GBS detection, identification and antibiotic-sensitivity results from samples collected in as little as 6 hours, a sharp contrast to traditional laboratory test times of 48-72 hours. One major goal in the study was to ensure the ability to test for antibiotic sensitivity in reduced time from the standard, potentially enabling physicians to rapidly tailor antibiotics to the actual infection involved and reduce the overuse of broad spectrum antibiotics.
  • Aug 15, 2012: NanoLogix is pleased to announce that the company will begin commercial marketing of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first to be marketed will be the BNP sandwiched-membrane petri kit with TSA media. BNP kits with other nutrient media will be available in the near future by special order. Thereafter, NanoLogix plans to expand commercial operations to marketing its BNF technology for ultra-fast identification of specific subject microorganisms. The company plans to introduce commercial applications for commonly tested microorganisms, but will also work to develop client-specific customized test kits for particular applications.
    The company will also initiate sales of TSA petri plates. Both BNP and Petri plates will be packaged in the company's proprietary vacuum Flat Packs. In addition, the final results of both the University of Texas Health Science Center.Houston's clinical study for Group B Strep in pregnancies, and a large third-party research and development organization's Tuberculosis laboratory study have been submitted, by each respective institution, to major peer-reviewed medical journals for publication. One paper details the final results of the 356-patient Group B Streptococcus clinical study at the University of Texas Health Science Center in Houston. The other paper features data from the third-party laboratory responsible for using NanoLogix BNP test kits to achieve detection of live Tuberculosis colonies in five days compared to the 21-28 days attainable through normal culturing.
  • July 9, 2012: University of Texas Health Science Center - Houston clinical study interim results, utilizing NanoLogix diagnostic technology, were presented at the 112th Annual meeting of the American Society for Microbiology in San Francisco from June 16 - 19, 2012. Authors of the research include Jonathan Faro MD, Ph.D, Karen Bishop MS, Gerald Riddle MS, Allan Katz MD, and Sebastian Faro MD. These interim results demonstrate clinical efficacy of NanoLogix technology. The clinical study included a pool of 300 pregnant women, tested for antibiotic sensitivity in the presence of Group B Streptococcus (GBS). --> View presentation poster
  • July 5, 2012: NanoLogix Announces Vendor Status
    The company is pleased to announce it has been selected as a vendor by a multi-billion dollar US research and development corporation. The corporation has notified NanoLogix it intends to use approximately 12,000 units of NanoLogix detection technology for a project beginning in July 2012. This marks the first large sale of NanoLogix technology.
  • May 21, 2012: Updates to Cleanroom Manufacturing Operation

    NanoLogix has recently completed major changes and updates to the cleanroom manufacturing operation. These enhancements have been implemented to optimize product quality and the manufacturing process. A computerized, state of the art, environmental monitoring system designed by LIGHTHOUSE Worldwide Solutions has been installed and is in operation. This system continuously monitors air quality, temperature, humidity, and air pressure on a real-time basis. Our cleanroom air filtration system has been re-designed to maximize the quality of the air within the space. The air filtration system has been upgraded to include 10 high-quality AIRGUARD filters, thus enabling our manufacturing space to operate at a solid ISO 6 level in a static mode as described within ISO 14644-1 Cleanroom Standards.

    NanoLogix Clean Room
  • May 14, 2012: Data Collection Completed for Group B Strep Clinical Study

    NanoLogix has reached a milestone with the completion of a 352-patient clinical study focused on rapid detection of Group B Streptococcus in pregnant patients. Conducted at University of Texas Health Science Center in Houston under Jonathan Faro, PhD, MD, the study confirms dramatic improvements in detection, identification, and determination of the antibiotic sensitivity of Group B Streptococcus with results for the entire process in 6 hours or less.

    This represents the latest phase in the evolution of NanoLogix technology within the past eighteen months. Revision of testing protocols during that time have led to results significantly faster and more specific than in initial tests done with NanoLogix products in 2010. This clinical study also marks the first time NanoLogix technology has been used with samples from human patients. Clinical studies, as opposed to clinical trials, are limited to research without medical intervention. NanoLogix anticipates the next step to be a clinical trial with medical intervention.

    The results of the completed clinical study are being prepared for publication in a major peer-reviewed medical science journal. The information on results of the 352-patient sampling is being submitted to the FDA as a non-invasive diagnostic kit application, with results forwarded to both the Centers for Disease Control and the World Health Organization.

    The University of Texas Health Science Center has recently revised its regulations for staff involvement with private companies. In order to comply with this change, Drs. Sebastian Faro and Alan Katz have resigned from the NanoLogix Science Advisory Board. Both Dr. Faro and Dr. Katz will continue to participate in research involving NanoLogix technology.
  • April 8, 2012: 2012 General Meeting of American Society for Micobiology

    Results of use of NanoLogix BNF technology will be presented at the 2012 General Meeting of the American Society for Microbiology in San Francisco, June 16-19, 2012 by Dr. Jonathan Faro of the University of Texas Health Science Center-Houston. Dr. Faro is the lead researcher in the 350-patient Group B Streptococcus clinical study being conducted at UTHSC-Houston. The study has currently passed the 330-patient point.
  • March 27, 2012: Society for Gynecologic Investigation - 2012 Annual Scientific Meetin

    University of Texas Health Science Center GBS research using NanoLogix technology was presented in poster form at the Society for Gynecologic Investigation - 2012 Annual Scientific Meeting, (March 21-24, 2012). Lead physician on the research Dr. Jonathan Faro states, "We were very happy to have had the opportunity to present our poster at the 59th annual scientific meeting of the Society for Gynecologic Investigation in San Diego. This was a terrific opportunity to share our research with other investigators, and we were happy to see that our initial data showing that GBS may be detected in under one hour was well received. There was a genuine interest by several clinicians in this assay, and we hope to provide them with further data in the near future." View the poster here>>
  • March 2, 2012: NanoLogix has registered to exhibit at the Food Safety Summit, April 17-19 in Washington, DC, (booth # 517).
  • February 28, 2012: ASM BioDefense and Emerging Diseases Research Meeting

    NanoLogix is currently exhibiting at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, on display at booth # 27, is receiving strong interest.
  • February 13, 2012 UTHSC Group B Strep Exhibited in Poster Presentation

    Group B Strep research from University of Texas Health Science Center presented at the poster session of the Society for Maternal-Fetal Medicine’s 32rd Annual Meeting in Dallas, TX (February 6-11, 2012). View the poster here>>
  • February 13, 2012: NanoLogix to Exhibit at ASM BioDefense and Emerging Diseases Research Meeting

    This month, NanoLogix will exhibit at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, including BNP and BNF will be on display at booth # 27.
  • February 9, 2012

    Over the past year, major developments at NanoLogix have drawn the attention of food processors, medical and veterinary facilities, universities, major diagnostic kit producers, government agencies, large and small clinics and hospitals, and various labs. Interest in our products continues to grow among both domestic and international entities.

    The comprehensive operations summary of 2011, which covers technology advances, partnership collaborations, preparations for FDA approvals, media coverage, financial information and the company’s new R&D laboratory.

    Read the full operations summary here>>
  • January 12, 2012: NanoLogix Joins WHO StopTB Partnership

    NanoLogix is pleased to announce it has been accepted as a member to the World Health Organization’s Stop TB Partnership. The organization consists of nearly 1000 partner members who are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programs, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector. More information on NanoLogix membership in the StopTB Partnership can be found at http://www.stoptb.org/partners/partner_profile2.asp?PID=69342.

2011

  • June 7, 2011: NanoLogix technology to be used for detection of E. coli strain found in Germany’s outbreak

    The company has added the E. coli 0104:H4 to the battery of bacteria being tested with NanoLogix technology by a major U.S. Biodefense contractor. E. coli 0104:H4 has been added in the interest of world health and the company plans to share its results with the appropriate U.S. and international bodies fighting foodborne illnesses.

    Since May 2, 2011, E. coli 0104:H4 has killed 23 people and sickened over 2300. So far, officials estimate that the agriculture industry in Spain is losing €200m a week and German famers are losing about €1m a day as a result.
  • May 31, 2011: The company had a very successful exhibit at the American Society for Microbiology General Meeting in New Orleans last week. Interest was renewed with a Japanese firm and new interest was generated from various parties including the US Navy, US Army, USDA, and the Centers for Disease Control and Prevention (Atlanta).

    Based on the success of the ASM and other business building activities, the company will be shipping BNP and BNF kits to the USDA next week for testing and to a major food processing company in a few weeks.

    Also this week, the first phase of the University of Texas Health Science Center clinical trial was accepted for publication by a major peer-reviewed journal. The name of the journal will be announced upon publication of the UTHSC paper.
  • May 23, 2011: The company is exhibiting this week at the 2011 General Meeting of the American Society of Microbiology in New Orleans. The conference runs through May 24th. View the booth display>>
  • April 15, 2011: NanoLogix is honored to have been chosen as one of three finalistsfor Outstanding Biotech Innovation, in the Cincinnati USA Regional Chamber and CincyTech 2011 Innovation Awards. NanoLogix congratulatesBexion Pharmaceuticalson winning the award for their research on drug development for identification of early indicators of tumor growth.
  • April 1, 2011: NanoLogix featured in April issue of Medical Laboratory Observer magazine.
  • February 18, 2011: NanoLogix featured in Lab Manager Magazine "Bacterial culturing for faster detection"
  • February 3, 2011: NanoLogix Nominated for Cincinnati USA Regional Chamber and CincyTech Innovation Award

    NanoLogix has been nominated for a Cincinnati USA Innovation Award in the category of: Outstanding Biotech Innovation – Small Business – a company with fewer than 50 employees that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenomics.

    The goal of the program, which is organized by the Cincinnati USA Regional Chamber, the Business Courier, and CincyTech, is to recognize innovative products and services at all levels of the business community that are aimed at spurring the development of new ideas as an economic engine. NanoLogix was nominated for the award by Carol Frankenstein, President of BIOStart in Cincinnati.
  • February 3, 2011: UT Houston Clinical Trial Update

    Jonathan Faro, MD, Ph.D, UTHSC-Houston Ob/Gyn Chief Resident and head of the study stated: "Regarding active studies with GBS utililizing NanoLogix technology, we at UT Houston have been very pleased with our initial results. We recently submitted an abstract of the first phase results to the American Society For Microbiology (ASM) and anticipate presenting our data at the annual ASM conference in New Orleans this May. If accepted, this presentation will highlight the first phase of the project which focuses on development of the assay and will form the foundation for the 300-patient clinical trial which is underway."
  • January 27, 2011: NanoLogix featured in hiVelocity Media

2010

  • November 24, 2010: Internal Update, Engaged Services of major defense organization

    NanoLogix has engaged the services of a major biodefense and biomedical research corporation to evaluate the NanoLogix BNF technology for detection and identification of six types of bacteria. This series of tests will include Vibrio cholerae (Cholera). The study is being funded by NanoLogix
  • August 25, 2010: New Patent Granted

    The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
  • August, 20, 2010: NanoLogix featured in this month’s issue of Medical Design Technology magazine, Speeding Up Petri Dish Diagnostics. “Petri dish technology is used around the world and the sandwiched-membrane BioNanoPore (BNP) test kits hold the potential to change diagnostics across the board."
  • August, 20, 2010: BNF technology highlighted in ADVANCE

    NanoLogix BNF technology highlighted in ADVANCE for Administrators of the Laboratory, NanoLogix and UT Medical Center Shorten Wait Times for Group-B Streptococcus Tests. “ NanoLogix Inc. offers its BNF technology in controlled testing at the University of Texas-Texas Medical Center in Houston for the bacteria Group B Streptococcus (GBS) in pregnant women.
  • August 9, 2010: This week, CEO Bret Barnhizer travels to Europe for meetings. Later this month, he and Dr. Sergey Gazenko will travel to Japan.
  • June 30, 2010: NanoLogix has filed and received medical device registration approval from the U.S. FDA for their BNPBNF and BNCtest kits. Registration number: 3005553828.
  • June 24, 2010: The Company has received the remaining 10 machines ordered from New Brunswick Scientific. 'NBS' personnel will be in-house June 29 to complete setup and inspection of the equipment.
    Copyright 2011 Nano
  • June 22, 2010: Collaboration With University of Texas Medical Center

    Our collaboration with the Texas Medical Center has produced preliminary culture-based results for the rapid detection of Group-B Streptococcus of between 4-6 hours. The initial results are 12-18 times faster than the 72 hour wait time experienced with traditional petri technology. The Texas Medical Center is continuing to finalize these Group-B Strep results and NanoLogix is furnishing additional test kits for that purpose.

    In addition, the physicians at the Medical Center will begin testing NanoLogix BNF/BNP technologies with the drug-resistant ‘superbug’ MRSA (methicillin resistant Staphylococcus aureus). MRSA is a type of staph infection that is the top cause of infections in hospitals. It traditionally takes 1-3 days to detect MRSA. Physicians at the Texas Medical Center anticipate that the NanoLogix technologies will dramatically reduce wait times for the detection of MRSA similar to the results evidenced by their recent test times for Group-B Strep.
  • May 20, 2010: Negotiations to purchase corporate headquarters
  • May 12, 2010: NanoLogix has received and installed the first two machines of the twelve ordered from New Brunswick Scientific. We anticipate the balance of the equipment ordered to arrive in May or June. This brings the total machines installed in the production clean room to six, equaling three complete workstations.
  • April 23, 2010: This week the company ordered new equipment from New Brunswick Scientific. This order is for six MP-1000 Automated Plate Pourers and six MM9 MediaMatic Sterilizers. This equipment will add six workstations to the existing Hubbard, Ohio cleanroom production facility.
  • April 13, 2010: On 12 April it came to the attention of NanoLogix management that there has been a statement released by an organization called The Street Alert (TSA), purportedly paid for by an organization named D3 Communications LLC, advising readers to take notice of our stock. Neither management, known affiliates, nor employees of NanoLogix have had any dealings whatsoever with either of these two entities.
  • April 9, 2010:The company announces that it is adding two microbiologists and an additional lab tech to their Research and Development facility in Cincinnati at Bio/Start. NanoLogix is also moving their current R&D to larger labs within the Bio/Start facility in order to accommodate up to eight research personnel for the foreseeable future.
  • April 8, 2010:After meetings in Houston, Texas, NanoLogix would like to announce that it is expanding its involvement with physicians at the Texas Medical Center significantly beyond that which has been ongoing since September of 2009. This work has been focused on providing early detection of infectious disease. Further details will be released in the near future.
  • March 26, 2010: The company would like to announce that it has completed construction of its cleanroom production facility. Completion was delayed from the original date by the decision to add an additional cleanroom thereby increasing the potential work stations from thirty-four to fifty-six. Over the next two weeks the company will be performing extensive cleaning of the facility, test runs on the two existing work stations, system tests, and preparing for the installation of additional New Brunswick Scientific equipment currently under order.
  • January 31, 2010: Items of Interest

    CEO Bret Barnhizer and Director John Chatterton have just returned from a week-long trip to the Middle Eastern countries of Kuwait and the UAE. In Kuwait they were hosted as guests of Dr. Eyad Al Saleh, CEO of the Advanced Medical German Company (AMGKWT), an operator of medical laboratories in the country. While in Kuwait, Barnhizer and Chatterton met with various officials. During their visit they toured the Royale Hayat Hospital and five laboratories owned and operated by AMGKWT.

    Following their Kuwait visit they traveled to Dubai, United Arab Emirates, where they attended Arab Health 2010 at the Dubai International Exhibition Center, again at the invitation of AMGKWT. The overall purpose of the trip was to assess the market potential for BNP and other NanoLogix products in the Middle East region, with the initial distribution focus to be on the Gulf Cooperation Council (GCC) states.

2009 Updates

  • November 25, 2009: Calendar of Events

    NanoLogix wishes to extend an invitation to interested parties to visit with company science staff and management at the 8th Annual ASM BioDefense Meeting to be held at the Baltimore Marriott Waterfront Hotel, Baltimore, Maryland from Sunday, February 21 to Wednesday, February 24, 2010. NanoLogix personnel can be visited at booth number 29. NanoLogix BNP/BNF and BNC technology will be on display. Information about the meeting can be accessed here and the floor plan of the exhibition can be viewed here.

    The Company also wishes to extend an invitation to interested parties to visit us at booth number 1313 at the ASM 110th Annual General Meeting to be held in San Diego, California from Sunday, May 23 to Thursday, May 27, 2010. Details of the General Meeting can be accessed here.
  • October 12, 2009: See our latest article: "NanoLogix Looks to Change How Lab Tests Are Done" in the Youngstown Vindicator's Business Section.
  • October 6, 2009: Operations Update

    NanoLogix is in the process of redirecting the Company’s primary focus from research and development to manufacturing. We have begun preparations for construction of a manufacturing facility to produce our BNP Rapid Detection Kits. Production operations will take place at the company's headquarters in Hubbard, Ohio, where we are negotiating the construction and build-out of existing leased footage in addition to possible expansion of our lease area. We are awaiting quotes from providers of modular clean-rooms for finalization of the production area design. The Company has chosen New Brunswick Scientific’s MP-1000 PourMatic® and associated equipment for use in the BNP kit production process. Production with the selected equipment is scalable to 48,000 kits per week, a capability that should enable us to meet the initial needs of a select group of customers and achieve our short term revenue goals.

    Ongoing testing conducted by both NanoLogix and their clients has confirmed that the BNP Rapid Test Kit technology has determined the viability of all micro-organisms tested to date in time spans that are 100 to 400 per cent faster than any competing technologies.
  • September 22, 2009: NanoLogix Inc. Confirms Date of Shareholder Meeting, Provides Operations Update

    NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST.

    Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009. The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
  • August 17, 2009: Announcement of 2009 Shareholder’s Meeting

    NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST. Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009.

    The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
  • July 27, 2009: Technology Breakthrough, Shipment Of Test Kits To Africa and Retainment of Patent Rights

    During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

    This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

    NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

    Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

    The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

    September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
  • July 06, 2009: Operations update and items of interest

    During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

    This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

    NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

    Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

    The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

    September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
  • June 18, 2009: ASM and Operations Update

    NanoLogix attended the American Society for Microbiology 109th General Meeting from May 18 – 20, 2009 in Philadelphia, PA. There was tremendous interest in the company's BNP technology from corporations involved in diagnostic testing, the pharmaceutical industry, governmental agencies, medical laboratories, environmental organizations, and universities. The BNP kits are currently undergoing evaluation by a number of those who demonstrated interest.

    Construction of a clean room production facility at our Hubbard, Ohio headquarters is ongoing. Upon completion, BNP kit production will be shifted from our Cincinnati lab to the new facility, with BNP kit production anticipated to begin this summer.
  • April 20, 2009: NanoLogix Begins Construction of Production Facility for Medical Test Kits
  • March 17, 2009: Operations Update - American Society for Microbiology (ASM) Meeting

    NanoLogix will attend the American Society for Microbiology (ASM) annual meeting, to be held in Philadelphia, PA May 17 – 21. The company will display at booth #749 in Exhibit Hall B at the Pennsylvania Convention Center, 1101 Arch Street, Philadelphia, PA 19107. More information is available at http://gm.asm.org/